Home > Insider Trading > Filing (0001562180-20-007457)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1560241	G1 Therapeutics Inc.	GTHX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184420	Seth Rudnick	700 Park Offices Drive, Suite 200 Research Triangle Park NC 27709		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-22	18,974	$20.33	19,308	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-12-23	13,118	$20.18	6,190	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
The price represents the weighted average price with a low of $20.00 and a high of $20.45. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
These shares are held in the Seth A. Rudnick 2014 GST Trust U/A Dated 03/01/2014 (the "Trust") for the benefit of the Reporting Person's heirs. The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The price represents the weighted average price with a low of $20.00 and a high of $20.44. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.